| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 21 Apr 2025 | 21 Apr 2025 |
| Update from Material Subsidiary on its proposed investment Intimation by Material Subsidiary on the Investment (As Per BSE Announcement Dated on 23.04.2025) | ||
| Board Meeting | 26 Mar 2025 | 24 Mar 2025 |
| Fischer Medical Ventures Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/03/2025 inter alia to consider and approve Change in Independent Director and other related and General Corporate Purpose Outcome of the Board Meeting held on 26th March 2025 (As per BSE Announcement Dated on 26/03/2025) Fischer Medical Ventures Limited has informed the exchange on the reconstitution of Committees of the Board. (As Per BSE Announcement Dated on 27.03.2025) | ||
| Board Meeting | 18 Feb 2025 | 18 Feb 2025 |
| Fischer Medical ventures Limited(Formerly known as Fischer Chemic Limited) as informed the exchange on the outcome of Board meeting held on 18-02-2025 relating to allotment of equity shares and warrants through preferential issue. | ||
| Board Meeting | 14 Feb 2025 | 7 Feb 2025 |
| Fischer Medical Ventures Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve Unaudited Financial results for the quarter ended 31.12.2024 and other incidental business matters Fischer Medical Ventures Limited (formerly known as Fischer Chemic Limited) has informed the exchange on the unaudited financial results for the quarter ended 31.12.2024 (As Per Bse Announcement Dated on 14.02.2025) | ||
| Board Meeting | 3 Jan 2025 | 28 Dec 2024 |
| Fischer Medical Ventures Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/01/2025 inter alia to consider and approve 1. The withdrawal of the proposed preferential issue which was announced by the Company on December 26 2024; 2. The proposal for fund raising by way of preferential issue / private placement of securities for cash / other than cash including determination of Issue Price subject to such regulatory/statutory approvals as may be required including the approval of shareholders of the Company.; 3. The day date time and venue for Extra-Ordinary General Meeting of the Company; 4. The notice for Extra-Ordinary General Meeting (EOGM) of the Company; 5. To fix the date for book closure (Register of Member); 6. To appoint Mr. Nuren Lodaya Practicing Company Secretary (Membership No. 60128) proprietor of M/s. Nuren Lodaya & Associates. as Scrutinizer for conducting e-voting and poll process for General Meeting of the Company; 7. To transact other incidental and ancillary matters as may be decided by the Board with the permission of Chairperson. Outcome of Board Meeting is enclosed herewith (As Per BSE Announcement Dated on: 03/01/2025) | ||
| Board Meeting | 13 Nov 2024 | 5 Nov 2024 |
| Fischer Medical Ventures Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Unaudited Standalone and Consolidated results for the quarter and half year ended 30.09.2024 and any other business matters OUTCOME OF BOARD MEETING (As Per BSE Announcement Dated on 14.11.2024) | ||
| Board Meeting | 14 Aug 2024 | 9 Aug 2024 |
| Fischer Medical Ventures Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve Unaudited standalone and consolidated Financial results for the period ended 30/06/2024 and also to consider fund raising through preferential issue for cash and non-cash consideration UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2024 (As Per BSE Announcement dated on 14.08.2024) Revised outcome with respect to typography error in the Annexure 2 relating to preferential issue without any change in the financial figures (As Per BSE Announcement dated on 15.08.2024) Revised outcome (As Per BSE Announcement Dated on 15.10.2024) | ||
| Board Meeting | 30 May 2024 | 21 May 2024 |
| FISCHER CHEMIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve audited Standalone and Consolidated Financial Results for the year and quarter ended 31.03.2024 Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) has informed the exchange on the approval of audited Standalone and Consolidated Financial Results for the quarter and year ended on 31.03.2024 Fischer Medical Ventures Limited (formerly known as Fischer Chemic Ltd) has informed the exchange on the approval of Board of Directors of the Company the Audited Standalone and Consolidated Financial Results for the quarter and year ended 31.03.2024 (As Per BSE Announcement dated on 30.05.2024) Revised outcome (As per BSE Announcement Dated on 10/09/2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
